Literature DB >> 20924111

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

Michele W L Teng1, Shin Foong Ngiow, Bianca von Scheidt, Nicole McLaughlin, Tim Sparwasser, Mark J Smyth.   

Abstract

Foxp3 is a central control element in the development and function of regulatory T cells (Treg), and mice expressing a diphtheria toxin (DT) receptor-enhanced green fluorescent protein fusion protein under the control of the foxp3 gene locus (DEREG mice) allow conditional and efficient depletion of Foxp3(+) Treg by DT injection. Herein, we use DEREG mice and a mouse model of carcinogenesis to show that conditional and effective Treg depletion can both protect mice from carcinogenesis by innate control, yet permanently eradicate a proportion of de novo-established tumors in mice in a largely CD8(+) T-cell- and IFN-γ-dependent manner. Tumors displayed a heterogeneous response to Treg depletion, and suppression of established tumors was accompanied by an increase in the tumor-infiltrating CD8(+) T-cell/B-cell ratio. Tumor rejection occurred in the absence of overt autoimmunity, suggesting that effective transient Treg depletion strategies may be therapeutic in at least a proportion of spontaneous tumors developing in the host. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924111     DOI: 10.1158/0008-5472.CAN-10-1681

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  88 in total

1.  Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis.

Authors:  Haris G Vikis; Andrew E Gelman; Andrew Franklin; Lauren Stein; Amy Rymaszewski; Jihong Zhu; Pengyuan Liu; Jay W Tichelaar; Alexander S Krupnick; Ming You
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

2.  Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer.

Authors:  T A Zikos; A D Donnenberg; R J Landreneau; J D Luketich; V S Donnenberg
Journal:  Cancer Immunol Immunother       Date:  2011-03-05       Impact factor: 6.968

3.  Reigning in regulatory T-cell function.

Authors:  Catherine Konopacki; George Plitas; Alexander Rudensky
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908

4.  Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ.

Authors:  Chang Liu; Maria Chikina; Rahul Deshpande; Ashley V Menk; Ting Wang; Tracy Tabib; Erin A Brunazzi; Kate M Vignali; Ming Sun; Donna B Stolz; Robert A Lafyatis; Wei Chen; Greg M Delgoffe; Creg J Workman; Stacy G Wendell; Dario A A Vignali
Journal:  Immunity       Date:  2019-07-23       Impact factor: 31.745

Review 5.  Exploring alternative treatments for Helicobacter pylori infection.

Authors:  Guadalupe Ayala; Wendy Itzel Escobedo-Hinojosa; Carlos Felipe de la Cruz-Herrera; Irma Romero
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

6.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

Review 8.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

9.  Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Authors:  Heidi Harjunpää; Stephen J Blake; Elizabeth Ahern; Stacey Allen; Jing Liu; Juming Yan; Viviana Lutzky; Kazuyoshi Takeda; Amy Roman Aguilera; Camille Guillerey; Deepak Mittal; Xian Yang Li; William C Dougall; Mark J Smyth; Michele W L Teng
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

10.  Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.

Authors:  Joshua P Landreneau; Michael R Shurin; Marianna V Agassandian; Anton A Keskinov; Yang Ma; Galina V Shurin
Journal:  Cancer Microenviron       Date:  2013-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.